Abstract
At JADPRO Live 2025, speakers discussed the latest safety and efficacy evidence behind recently approved therapies for myelodysplastic syndromes, implementing adverse event monitoring and management plans to support adherence and patient safety, and integrating current evidence into treatment decisions to reduce transfusion dependence and improve quality of life for patients with MDS.
References
AbbVie. (2025). AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes. https://news.abbvie.com/2025-06-16-AbbVie-Provides-Update-on-VERONA-Trial-for-Newly-Diagnosed-Higher-Risk-Myelodysplastic-Syndromes
Garcia, J. S., Platzbecker, U., Odenike, O., Fleming, S., Fong, C. Y., Borate, U., Jacoby, M. A., Nowak, D., Baer, M. R., Peterlin, P., Chyla, B., Wang, H., Ku, G., Hoffman, D., Potluri, J., & Garcia-Manero, G. (2025). Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood, 145(11), 1126–1135. https://doi.org/10.1182/blood.2024025464
Platzbecker, U., Della Porta, M. G., Santini, V., Zeidan, A. M., Komrokji, R. S., Shortt, J., Valcarcel, D., Jonasova, A., Dimicoli-Salazar, S., Tiong, I. S., Lin, C. C., Li, J., Zhang, J., Giuseppi, A. C., Kreitz, S., Pozharskaya, V., Keeperman, K. L., Rose, S., Shetty, J. K., Hayati, S., … Garcia-Manero, G. (2023). Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet (London, England), 402(10399), 373–385. https://doi.org/10.1016/S0140-6736(23)00874-7
Platzbecker, U., Santini, V., Fenaux, P., Sekeres, M. A., Savona, M. R., Madanat, Y. F., Díez-Campelo, M., Valcárcel, D., Illmer, T., Jonášová, A., Bělohlávková, P., Sherman, L. J., Berry, T., Dougherty, S., Shah, S., Xia, Q., Sun, L., Wan, Y., Huang, F., Ikin, A.,…Zeidan, A. M. (2024). Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): A multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England), 403(10423), 249–260. https://doi.org/10.1016/S0140-6736(23)01724-5
Seghers, P. A. L. N., Wiersma, A., Festen, S., Stegmann, M. E., Soubeyran, P., Rostoft, S., O’Hanlon, S., Portielje, J. E. A., & Hamaker, M. E. (2022). Patient preferences for treatment outcomes in oncology with a focus on the older patient-a systematic review. Cancers, 14(5), 1147. https://doi.org/10.3390/cancers14051147
